KYMR vs DBVT vs IMVT vs SNY vs ABBV

For growth investors, AbbVie Inc.

(ABBV) is the stronger pick with 8. 6% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). Sanofi (SNY) offers the better valuation at 18. 1x trailing P/E (10. 3x forward), making it the more compelling value choice. Analysts rate Kymera Therapeutics, Inc. (KYMR) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Sanofi (SNY) is the cheapest at 18.

1x versus AbbVie Inc. at 85. 5x. On forward P/E, Sanofi is actually cheaper at 10. 3x.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +101. 3%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: ABBV returned +295. 5% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 34β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 306% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 30% for Sanofi — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AbbVie Inc.

(ABBV) is pulling ahead at 8. 6% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: AbbVie Inc. grew EPS -0. 8% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, SNY leads at 4. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Sanofi (SNY) is the more profitable company, earning 16.

7% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 16. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sanofi (SNY) trades at 10.

3x forward P/E versus 14. 3x for AbbVie Inc. — 4. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

In this comparison, SNY (5.

1% yield), ABBV (3. 2% yield) pay a dividend. KYMR, DBVT, IMVT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Both have compounded well over 10 years (ABBV: +295. 5%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KYMR is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; IMVT is a small-cap quality compounder stock; SNY is a mid-cap income-oriented stock; ABBV is a large-cap income-oriented stock. SNY, ABBV pay a dividend while KYMR, DBVT, IMVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.